Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-Week results of the VIKING study

1. Eron, J.J.
2. Clotet, B.
3. Durant, J.
4. Katlama, C.
5. Kumar, P.
6. Lazzarin, A.
7. Poizot-Martin, I.
8. Richmond, G.
9. Soriano, V.
10. Ait-Khaled, M.
11. Fujiwara, T.
12. Huang, J.
13. Min, S.
14. Vavro, C.
15. Yeo, J.
16. Walmsley, S.L.
17. Cox, J.
18. Reynes, J.
19. Morlat, P.
20. Vittecoq, D.
21. Livrozet, J.-M.
22. Fernández, P.V.
23. Gatell, J.M.
24. DeJesus, E.
25. DeVente, J.
26. Lalezari, J.P.
27. McCurdy, L.H.
28. Sloan, L.A.
29. Young, B.
30. LaMarca, A.
31. Hawkins, T.
32. Show all authors +

Export

Export

×

MLA

modern-language-association

APA

apa

Chicago

chicago-fullnote-bibliography

Harvard

harvard-cite-them-right

Vancouver

vancouver-author-date

---

RIS BibTex

Export

×

This document cannot be exported because it belongs to another portal.

Full text

lock_openFull text externo

DOI: 10.1093/INFDIS/JIS750 GOOGLE SCHOLAR lock_openOpen access editor

Sustainable development goals

• 

Data source: Scopus